参考文献/References:
[1] Sargis RM,Subbaiah PV.Protection of membrane cholesterol by sphingomyelin against free radical-mediated (nidation.Free Radic Biol Med,2006,40(12):2092-2102.
[2] Stadtman ER,Levine RL Free radical-mediated oxidation of free amino acids and amino acid residues in proteins.Amino Acids,2003,25(3^4):207-218.
[3] Dizdaroglu M,Jaruga P,Birincioglu M,et al.Free radical-induced damage to DNA:mechanisms and measurement.Free Radic Biol Med,2002,32(11):1102-1115.
[4] Ademo?lu E,Ozbey N,Erbil Y,et al.Determination of oxidative stress in thyroid tissue and plasma of patients with Graves’ disease.Eur J Intern Med,2006,17(8):545-550.
[5] Duthoit C,Estienne V,Giraud A,et al.Hydrogen peroxide-induced production of a 40 kDa iramunoreactive thyroglobulin fragment in human thyroid cells:the onset of thyroid autoimmunity?,Biochem J,200U360(pt 3):557-562.
[6] Komosinska-Vassev K,Olczyk K,Kucharz EJ,et al.Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy.Clin Chim Acta,2000,300(1-2):107-117.
[7] Bednarek J,Wysocki H,Sowiński J.Oxidative stress peripheral parameters in Graves’ disease:the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy.Clin Biochem,2005,38(1):13-18.
[8] Mayer L,Romi? Z,Skreb F,et al.Antioxidants in patients with hyperthyroidism.Clin Chem Lab Med,2004,42(2):154-158.
[9] Abalovich M,Uesuy S,Gutierrez S,et al.Peripheral parameters of oxidative stress in Graves’ disease:the effects of methimazole and 131iodine treatments.Clin Endocrinol,2003,59(3):321-327.
[10] Fcmdndcz V,Cornejo P,Tapia G, et al.Influence of hyperthyroidism on the activity of liver nitric oxide synthase in the rat.Nitric Oxide,1997,1(6):463-468,
[11] Colin IM,Kopp P,Zbären J,et al.Expression of nitric oxide synthase III in human thyroid follicular cells:evidence for increased expression in hyperthyroidism.Eur J Endocrinol,1997,136(6):649-655.
[12] López-Moratalla N,Calleja A,González A,et al.Inducible nitric oxide synthase in monocytes from patients with Graves’ disease.Biochem Biophys Res Commun,1996,226(3):723-729.
[13] Gérard AC,Boucquey M,van den Hove MF,et al.Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-lalpha/IFN-gamma,an effect partially mediated by nitric oxide.Am J Physiol Endocrinol Metab,2006,291(2):242-253.
[14] Kiotz LO,Schroeder P,Sies H.Peroxynitrite signaling:receptor tyrosine kinases and activation of stress-responsive pathways.Free Hadic Biol Med,2002,33(6):737-743.
[15] Alturfan AA,Zengin E,Dariyerli N,et al.Investigation of zinc and copper levels in methimazole-induced hypothyroidism:relation with the oxidant-antioxidant status.Folia Biol (Praha),2007,53(5):183-188.
[16] Hondur A,Konuk O,Dincel AS,et al.Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy. Cuit Eye Res,2008,33(5):421-427,
[17] Mogulkoc R,Baltaci AK,Oztekin E,et al.Melatonin prevents oxidant damage in various tissues of rats with hyperthyroidism.Life Sci,2006,79(3):311-315.
[18] Moreno JM,Rodríguez Gómezl,Wangenstcen R,et al.Cardiac and renal antioxidant enzymes and effects of tcmpol in hyperthyroid rats.Am J Physiol Endocrinol Metab,2005,289(5):E776-E783.
[19] Dani V,Dhawan D.Zinc as an antiperoxidative agent following iodine-131 induced changes on the antioxidant system and on the morphology of red blood cells in rats.Hell J Nucl Med,2006,9(1):22-26.
[20] Agote Robertson M,Finochietto P,Gamba CA,et al.Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides.Horm Metab Res,2006,38(1):12-15.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[6]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[7]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[8]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[9]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[10]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]